GlaxoSmithKline, Theravance start Phase III trial of fluticasone furoate/vilanterol to treat COPD
The trial is designed to evaluate the contribution of the ICS component on lung function, in patients with Chronic Obstructive Pulmonary Disease (COPD). According to GSK, positive results